1 of 1
Story summary
- Gilead Sciences received FDA approval for lenacapavir as HIV prevention in June 2025.
- A 2024 trial of 2,000 South African and Ugandan women recorded zero HIV infections with lenacapavir.
- The World Health Organization recommended the long-acting injectable as an additional pre-exposure prophylaxis option.
- Gilead aims to provide lenacapavir for up to three million people through 2028, with generic rollout in 2027.
